These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2627052)

  • 1. An antihypertensive drug with polyfactor mechanism of action: urapidil.
    Van Zwieten PA; Prichard BN
    Ann Fr Anesth Reanim; 1989; 8(5):568-71, 528-31. PubMed ID: 2627052
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacological profile of antihypertensive drugs with serotonin receptor and alpha-adrenoceptor activity.
    van Zwieten PA; Blauw GJ; van Brummelen P
    Drugs; 1990; 40 Suppl 4():1-8; discussion 28-30. PubMed ID: 1982649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of urapidil on blood pressure and adrenoceptors in various animal models.
    van Zwieten PA; Mathy MJ; Thoolent MJ; Wilffert B; de Jonge A; Timmermans PB
    J Hypertens Suppl; 1984 Dec; 2(3):S539-41. PubMed ID: 6599713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central and peripheral hypotensive activity of urapidil and its M1 and M2 metabolites in the cat.
    Boss H; Boer R; Beller KD; Sanders KH
    Drugs; 1990; 40 Suppl 4():34-7. PubMed ID: 1982652
    [No Abstract]   [Full Text] [Related]  

  • 5. Importance of central nervous system serotonin-1A receptors for mediating the hypotensive effect of urapidil.
    Mandal AK; Kellar KJ; Friedman E; Pineo SV; Hamosh P; Gillis RA
    J Pharmacol Exp Ther; 1989 Nov; 251(2):563-70. PubMed ID: 2530339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of urapidil with brain serotonin-1A receptors increases the blood pressure reduction due to peripheral alpha-adrenoceptor inhibition.
    Sanders KH; Beller KD; Bischler P; Kolassa N
    J Hypertens Suppl; 1988 Dec; 6(2):S65-8. PubMed ID: 2906703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacologic bases of antihypertensive drugs with mechanisms of multi-factor action].
    Van Zwieten PA
    Therapie; 1990; 45 Suppl 2():177-82. PubMed ID: 1971122
    [No Abstract]   [Full Text] [Related]  

  • 8. Involvement of brain 5-HT1A receptors in the hypotensive response to urapidil.
    Kolassa N; Beller KD; Sanders KH
    Am J Cardiol; 1989 Aug; 64(7):7D-10D. PubMed ID: 2569265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ketanserin versus urapidil: age-related cardiovascular effects in conscious rats.
    Buñag RD; Thomas CV; Mellick JR
    Eur J Pharmacol; 2002 Jan; 435(1):85-92. PubMed ID: 11790382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of 5-HT1A receptors in blood pressure reduction by 8-OH-DPAT and urapidil in cats.
    Sanders KH; Beller KD; Kolassa N
    J Cardiovasc Pharmacol; 1990; 15 Suppl 7():S86-93. PubMed ID: 1702492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental studies on the neurocardiovascular effects of urapidil.
    Gillis RA; Kellar KJ; Quest JA; Namath IJ; Martino-Barrows A; Hill K; Gatti PJ; Dretchen K
    Drugs; 1988; 35 Suppl 6():20-33. PubMed ID: 2900129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular effects and interaction with adrenoceptors of urapidil.
    van Zwieten PA; de Jonge A; Wilffert B; Timmermans PB; Beckeringh JJ; Thoolen MJ
    Arch Int Pharmacodyn Ther; 1985 Aug; 276(2):180-201. PubMed ID: 4051641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonergic receptors and drugs in hypertension.
    van Zwieten PA; Blauw GJ; van Brummelen P
    Pharmacol Toxicol; 1992 Jun; 70(6 Pt 2):S17-22. PubMed ID: 1354865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of the hypotensive effect of ketanserin.
    Fozard JR
    J Cardiovasc Pharmacol; 1982; 4(5):829-38. PubMed ID: 6182416
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative effects of urapidil, prazosin, and clonidine on ligand binding to central nervous system receptors, arterial pressure, and heart rate in experimental animals.
    Kellar KJ; Quest JA; Spera AC; Buller A; Conforti A; Dias Souza J; Gillis RA
    Am J Med; 1984 Oct; 77(4A):87-95. PubMed ID: 6091452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-HT1A-agonistic properties of naftopidil, a novel antihypertensive drug.
    Borbe HO; Metzenauer P; Szelenyi I
    Eur J Pharmacol; 1991 Nov; 205(1):105-7. PubMed ID: 1839829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central 5-HT1A receptors and the mechanism of the central hypotensive effect of (+)8-OH-DPAT, DP-5-CT, R28935, and urapidil.
    Doods HN; Boddeke HW; Kalkman HO; Hoyer D; Mathy MJ; van Zwieten PA
    J Cardiovasc Pharmacol; 1988 Apr; 11(4):432-7. PubMed ID: 2453746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the antihypertensive properties of ketanserin (R 41 468) in rats.
    Kalkman HO; Timmermans PB; Van Zwieten PA
    J Pharmacol Exp Ther; 1982 Jul; 222(1):227-31. PubMed ID: 6283070
    [No Abstract]   [Full Text] [Related]  

  • 19. [Alpha 1 receptors and blood pressure control. Mechanisms of hypotensive action of urapidil?].
    Brisac AM
    Therapie; 1990; 45 Suppl 2():187-90. PubMed ID: 2160131
    [No Abstract]   [Full Text] [Related]  

  • 20. [The effect of the flesinoxan subtype of serotonin C1a receptor agonist on the arterial pressure in rats].
    Piianzin AI; Popova NK; Markel' AL
    Farmakol Toksikol; 1991; 54(4):28-30. PubMed ID: 1786817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.